Table 4. Treatment-emergent gene alterations detected in liquid biopsy samples collected at post-study treatment discontinuation visit.
| Gene alterations | RAM + ERL, n (%) | PL + ERL, n (%) | Overall, n (%) |
|---|---|---|---|
| Mutations detected by NGS† | |||
| EGFR‡ | 2 (22.2) | 5 (29.4) | 7 (26.9) |
| H870R | 1 (11.1) | 0 | 1 (3.8) |
| T790M | 2 (22.2) | 5 (29.4) | 7 (26.9) |
| FGFR3 | 1 (11.1) | 0 | 1 (3.8) |
| KRAS | 2 (22.2) | 0 | 2 (7.7) |
| TP53 | 3 (33.3) | 1 (5.9) | 4 (15.4) |
| None | 4 (44.4) | 11 (64.7) | 15 (57.7) |
| Mutations detected by ddPCR§ | |||
| T790M | 6 (54.5) | 7 (41.2) | 13 (46.4) |
†, RAM + ERL, N=9; PL + ERL, N=17; Overall, N=26; ‡, one patient had 2 treatment-emergent EGFR mutations (T790M and H870R); 3 patients did not have EGFR‑activating mutations detected in ctDNA at baseline but did have these mutations detected at 30-day post-study treatment discontinuation, consistent with their local baseline testing (2 exon 19 deletion, 1 L858R), and were not included in this treatment-emergent summary; §, RAM + ERL, N=11; PL + ERL, N=17; Overall, N=28. RAM, ramucirumab; ERL, erlotinib; PL, placebo; NGS, next-generation sequencing; ddPCR, droplet digital polymerase chain reaction; EGFR, epidermal growth factor receptor; ctDNA, circulating tumor DNA.